TerminatedPhase 2NCT04189952

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Miami
Principal Investigator
Craig Moskowitz, MD
University of Miami
Intervention
Acalabrutinib(drug)
Enrollment
2 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2022

Study locations (1)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04189952 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials